Scleromyxedema
Document Sample


Scleromyxedema
A Presentation of this rare case
and the problem we meet
2003/1/30
By R Liu Chih-Min
Introduction
EPIDEMIOLOGY
Scleromyxedema is an uncommon disease;
approximately 114 cases have been reported in the
Englishlanguage literature
It typically affects middle-aged adults without sex
predilection
Idiopathic cutaneous mucinosis
generalized VS localized lichen myxedematosus
Introduction
PATHOGENESIS
Paraprotein role
Paraprotein levels correlate with neither extent nor progression
of the disease. However, whereas scleromyxedema serum
enhances fibroblast proliferation, an immunoglobulin purified
from the paraprotein-containing serum proved unable to
stimulate fibroblasts to proliferate in vitro, which suggests a
pathogenetic role of a circulating factor other than the
paraprotein.
Introduction
HISTOLOGICAL TYPES
The histopathology is distinct for scleromyxedema with
collections of mucin associated with a marked
proliferation of fibroblasts in the upper and mid-dermis
Introduction
Diagnosis of scleromyxedema
(1) generalized papular and sclerodermoid eruption
(2) mucin deposition, fibroblast proliferation, and fibrosis
(3) monoclonal gammopathy
(4) the absence of thyroid disease
Introduction
DISEASE ASSOCIATIONS
Slight to severe muscle weakness
severe proximal muscle weakness is found in 27%
Mucin deposition has been found in only 2 patients
Paraproteinemia in scleromyxedema
Associated with many systemic disorders and, almost constantly, with
paraproteinemia (83.2%)
Usually IgG with light chains
Joints
Reported in 10.5% of the patients
Arthralgia, migratory arthritis, and seronegative polyarthritis with
occasional mucin deposition
Introduction
Lungs
Dyspnea is found in 16.7% of patients
Restrictive or obstructive lung involvement
Rarely pulmonary hypertension developed, mucin deposition was
found in the large pulmonary veins and artery
Disturbances of the central nervous system
15% of patients
Esophagus
Dysphagia and nasal regurgitation are reported by 31.6% of patients
Kidney
Heart
Optic
Larynx
Introduction
PROGNOSIS AND TREATMENT
Recurrence
Spontaneous improvement and resolution, even after 15 years,
have been described
Treatment
Corticosteroids; Retinoid
Response to high-dose intravenous immunoglobulin (hdIVIg).
Complete Remission of Scleromyxedema Following
Autologous Stem Cell Transplantation
History
<Basic data>
Sex: female
Age: 46 y/o
<Chief complaint>
Rapid growing hematoma noted on 2002/12/15
History
<Present illness>
2000/5: Progressive four limbs weakness
Proximal weakness and myalgia
2001/1: Admitted to CGMH
NCV, EMG revealed myopathy but muscle biopsy: (-)
2001/4: NTUH
Bedridden, joint cintracture
IgG elevation; Bences-Jones protine
Skin biopsy: mucin deposition
Scleromyxedema was diagnosted
Multiple systemic manifastation: myopath, dysphagia, serum
paraprotine elevation
History
<Present illness>
2002/12/15: Right thigh petechiae
Her family
Rapid extended to 5*5cm
Hematoma ruptured with wound necrosis
Wound debridement was arranged on 2002/1/8
Left knee subluxation
History
<Physical Examination>
Extrimity:
Right thigh 15*7cm hematoma with skin necrosis
Multiple joints contractures with deformity
Motor
MP: distal
DTR: (-)
Sensation: fine
<Impression>
Scleromyxedema
Right thigh hematoma with local cellulitis
About our patient in OR
2003/1/8
First operation for right thigh
hematoma debridement
Post-OP Complication
Spontaneous scalp hematoma
Massive hematoma evacuation. ( > 500ml)
PRBC 2U: Hb 9.9
Course
Wound:
Oozing; PRBC 6U + Cryoprecipitate 10U
Lab:
Bleeding time: 10.5 sec to > 20 sec
R/O platelet dysfunction
R/O VWF disease
2nd operation
2003/1/17
Protection and avoid stressful
sheering during operation
Course
<OP Note>
ETGA, prone
Diffuse oozing
Hard to close
Cover open wound
<Post-OP>
Still oozing
Hb: 12.2 to 5.4; PRBC 4U
Protection
Hematoma protected
and compression
Portection of face
Protection
Dislocation of hip joint
Diffuse oozing
Protection
Protection
Get documents about "